Posted on

Increased office presence to 50%

Given the progress of the vaccination campaign in Spain and as we had announced before the holidays, this committee has decided to review the percentage of face-to-face attendance in offices that will go from 30 to 50%.

The positions marked with the green sticker will be occupied, which guarantee the maximum distance between employees. The departments will organize the corresponding shifts with a proportion of 50% of face-to-face work and telework, ensuring that the workplace is attended at least once a week.

This decision affects all employees linked to the offices of non-industrial areas of ROVI and will apply from Monday, September 20.

Schedules
The transfer schedule remains as before:

  • WHEN THE DAY IS CARRIED OUT WORKING FROM HOME (as well as breakfast breaks).
  • WHEN IT TAKES PLACE AT THE VENUE: intensive shift (Flexible entry from 8-9 h. and departure 16-17 hours).

Canteens
The use of canteens continues as at present, restricted in the case of non-industrial office staff to the use of drinking fountains, vending or coffee machines.

Meetings
Physical meetings (between departments and with external personnel) will also be allowed in ROVI, but the maximum capacity allowed in each room will have to be respected.

Travel
In the same way, the realization of trips for work reasons is allowed. In both cases, meetings and travel, this committee recommends reducing both to the minimum necessary and continuing to make use of telematics applications where possible. It will be the responsibility of the heads of department to make decisions regarding meetings and travel that are necessary.

Mobility between venues
Mobility between venues will continue as before, with prior authorization from the head of the Department and notification to the covid-19 notification mailbox, avoiding possible excesses of capacity in our facilities.

The intention of this committee is to recover normality in our jobs safely and gradually, so these measures are provisional. If the evolution of the pandemic forces us to take additional measures, on October we will review these and other measures again.

Posted on

ROVI reports on the investigation into the recall of 3 batches of Moderna vaccine

In relation to the relevant information published in recent days on the recall of batches of Moderna’s Covid-19 vaccine because of the detection of particles in some vials distributed in Japan, ROVI reports the conclusions of the investigation carried out in collaboration with the Japanese Ministry of Health, Labour and Welfare, the vaccine’s proprietary laboratory, Moderna, and the authorised distributor in Japan, Takeda. 

On 26 August 2021, three batches of Moderna’s Covid-19 vaccine (batch 3004667, 3004734 and 3004956) were recalled following the discovery of foreign particles in unused vials of batch 3004667.

According to the cause investigation report conducted by ROVI, the most likely cause of the particulates identified in that batch is related to friction between two metal parts installed in the capping module of the production line due to an incorrect configuration during a line changeover prior to the start of production of batch 3004667.

According to ROVI’s analysis, the manufacturing incident only affected the three batches that were suspended and for which Takeda has requested a definitive recall.

ROVI, in coordination and in agreement with Moderna, has taken the appropriate measures to strengthen the processing and control protocols with the process requirements that have been revealed in relation to these new manufacturing activities in order to prevent potential incidents.

From ROVI’s Management we would like to send a message of thanks to the teams involved in the investigation of what happened, who have worked over the last few days with the utmost sense of urgency and displaying their professionalism and commitment.
Likewise, we convey our full support to these professionals who continue to work and offer solutions to ensure that our activity continues as normal.

Particulate analysis and safety assessment

According to the independent analysis carried out by Moderna, the particulate from batch 3004667  has been thoroughly analysed and is confirmed to be 316 grade stainless steel. This is consistent with the determination of the particle origin described  above. Grade 316 is a high grade of stainless steel commonly used in the manufacture and processing of stainless steel in food manufacturing and processing

Following a health assessment conducted by Moderna and Takeda, the rare presence of stainless steel particles in Moderna’s COVID-19 vaccine does not pose an undue risk to patient safety and does not adversely affect the benefit/risk profile of the product.

Metal particles of this size injected into a muscle may cause a local reaction, but are unlikely to cause other adverse reactions beyond the injection site. Stainless steel is commonly used in heart valves, joint replacements and metal sutures and staples. Therefore, injection of the particles identified in these batches in Japan is not expected to pose any major medical risk. 

Investigation into two deaths following vaccine administration

As reported by Moderna and Takeda in their press release, there is currently no evidence that the two tragic deaths that occurred following the administration of Moderna’s Covid-19 vaccine (from lot 3004734) were related to the administration of the vaccine. The link is now considered to be coincidental. However, both companies are conducting an investigation with the utmost sense of urgency to provide conclusions.

Posted on

Make your life more cybersecure…Keep an eye on your devices at all times!

Our devices and the information stored in them are very valuable, making them attractive targets for cyber attackers.

Remember that you are responsible for ensuring the safety of your ROVI devices, both inside and outside the office, so it is important to know how to protect them.

Click on the video to see two employees learning a hard lesson about the risk of theft!

Follow these tips to protect your devices:

  • Keep your devices at sight at all times
  • Try not to expose your devices too much: do not leave them on the table
  • Never ask anyone to take care of them, you are responsible for them
  • Store your backpack where you can see it or between your legs (never hang it on the back of the chair!)

Don’t forget to report thefts or any suspicious situation to the mailbox seguridadIT@rovi.es

#Protect your Information

Posted on

ROVI ranks 2nd in global sustainability rating

ROVI’s ESG (Environmental, Social and Governance) criteria were evaluated by Sustainalytics, a leading company in the evaluation of Corporate Social Responsibility and Corporate Governance at world level, having achieved an ESG risk rating of 18.4 points, which places the company in a low risk position (between 10 and 20 points). This rating improves by 3.4 points on the previous year (21.8 points), when the company reached a medium risk position (between 20 and 30 points).

In this classification, ROVI obtained the second best rating out of 432 companies evaluated in the pharmaceutical industry category and 17th out of a total of 896 companies in the sector, which includes biotechnology, pharmaceutical laboratories and healthcare equipment companies.

You can consult ROVI’s evaluation at THIS LINK

Posted on

The councilor for equality of Alcalá de Henares visits the ROVI plant

The Councilor for Equality in the Alcalá de Henares City Council, Patricia Sánchez, has visited ROVI’s facilities in the mentioned town. This plant has welcomed women from the course of operator of manipulation and production of the Chemical Industry, within the Program “Employment from Equality”.


During the visit, the councilor toured the facilities together with the director of the plant, Pilar García-Morato, and the Human Resources Manager, Beatriz Felipe.


Patricia Sánchez stressed the importance of this initiative that “promotes the employability of women, improving their expectations and quality of life through their personal development and a better qualification for employment”


In addition, she wanted to thank ROVI “for having welcomed women from the Program “Employment from Equality” for the realization of the 80 hours of practices with the aim of achieving a practical approach to the position of manipulation and production operator and facilitate their insertion in the labour market”.

Posted on

Make your life more cyber secure… Take care of confidential information on paper!

When we work with printed information, we must guard it securely, especially if it is confidential. It is important not to lower our guard, even when we are in a controlled environment, such as in the office or at home, to prevent information from falling into the wrong hands.  

Click and watch the next video from our series!

Tips for protecting confidential information:

  • Keep all confidential information in a locked drawer or cabinet.
  • For documents that you are not going to reuse, destroy them using a paper shredder.  
  • Always clean the board after your meetings.
  • If you need to print something, pick up your documents immediately and don’t leave anything in the tray.

Don’t forget to report any suspicious situation to the mailbox seguridadIT@rovi.es #ProtectYOURinformation

Posted on

ROVI reports operating revenue growth of 52% in the first half of 2021

ROVI released today its financial results for the first half of 2021. Below, we share some of the main indicators:

  • Operating revenue increased by 52% to 290.1 million euros in the first half of 2021, driven by the strength of the toll manufacturing business, which grew by 172%, and the specialty pharmaceutical business, where sales rose 25%.
  • Total revenue increased by 52% to 290.6 million euros in the first half of 2021.
  • Sales of the heparin franchise (Low Molecular Weight Heparins (LMWH) and other heparins) increased by 26% to 131.4 million euros in the first half of 2021.
  • Heparin sales represented 45% of operating revenue in the first half of 2021 compared to 54% in the first half of 2020.
  • Sales of LMWH (Enoxaparin biosimilar and Bemiparin) increased by 27% to 127.8 million euros in the first half of 2021. Sales of the enoxaparin biosimilar increased 27% to 62.7 million euros in the first half of 2021 and sales of Bemiparin increased 26% to 65.1 million euros.
  • EBITDA increased by 75%, from 42.4 million euros in the first half of 2020 to 74.0 million euros in the first half of 2021, reflecting a 3.3 percentage point rise in the EBITDA margin to 25.5% in the first half of 2021.
  • Net profit increased by 72%, from 29.6 million euros in the first half of 2020 to 51.0 million euros in the first half of 2021.
  • As a result of the expansion of the collaboration agreement with Moderna and the current visibility of ROVI’s business areas, the company has again upgraded its forecast for growth in operating revenue in 2021, raising it to between 35% and 40%


Posted on

Juan Lopez-Belmonte Encina, new Chairman of the Board of Directors

The Board of Directors of ROVI, at its meeting held today, has unanimously and acting
on a report from the Appointments and Remunerations Committee, agreed to appoint
the current Chief Executive Officer, Mr. Juan López-Belmonte Encina, as new Chairman
of the Board of Directors of ROVI.
The Board of Directors has expressed the profound gratitude and respect of the
Company and all of its employees towards the former Chairman, Mr. Juan López-Belmonte López.
The Appointments and Remunerations Committee has considered that according to
the career of Mr. Juan López-Belmonte Encina it is clear that he has unquestionable
knowledge to perform the functions as Chairman of the Board, as well as a deep and
extensive expertise in the Company, the Rovi Group and the sector in which it develops
its activity, making him the suitable candidate to occupy such position.
Mr. Juan López-Belmonte Encina will continue to act also as a Chief Executive Officer
(Consejero Delegado).